delet
howev
clear
similarli
sarscov
individu
februari
genet
divers
later
isol
spike
protein
viral
surfac
glycoprotein
mediat
viral
attach
entri
cell
fig
earli
isol
contain
higher
rate
nonsynonym
mutat
probabl
reflect
ongo
adapt
new
host
rel
genet
homogen
sarscov
isol
later
outbreak
may
reflect
viru
better
adapt
new
host
fact
much
global
spread
aros
one
index
case
hotel
hong
kong
may
also
contribut
genet
homogen
ban
sale
wildlif
wet
market
guangdong
impos
later
period
sar
outbreak
lift
septemb
decemb
januari
four
new
case
sar
first
nonlaboratoryassoci
case
diagnos
human
sinc
end
sar
outbreak
juli
epidemiolog
linkag
phylogenet
data
suggest
associ
virus
new
introduct
anim
guan
unpublish
observ
human
case
rel
mild
lead
secondari
transmiss
reflect
anim
precursor
viru
probabl
well
adapt
effici
humantohuman
transmiss
probabl
recapitul
event
late
runup
sar
outbreak
time
find
led
reintroduct
ban
wildgam
anim
market
natur
acquir
human
case
sinc
like
precursor
sarscov
repeatedli
cross
speci
barrier
occasion
succeed
adapt
humanhuman
transmiss
adapt
clearli
occur
late
may
happen
futur
given
present
understand
awar
sar
expect
reemerg
unlik
lead
global
outbreak
scale
major
rout
transmiss
sar
droplet
infect
aerosol
fomit
ref
world
health
organ
http
wwwwhointcsrsarsenwhoconsensuspdf
deposit
infect
droplet
aerosol
respiratori
mucos
epithelium
probabl
initi
viral
infect
whether
infect
occur
oral
conjunctiv
rout
unknown
sarscov
detect
tear
although
exposur
anim
precursor
figur
global
spread
sar
number
probabl
case
sar
date
onset
first
case
countri
group
countri
denot
countri
denot
red
substanti
local
transmiss
occur
data
base
world
health
organ
http
figur
adapt
ref
wet
market
guangdong
wet
market
sell
live
poultri
fish
reptil
mammal
commonplac
across
southeast
asia
southern
china
servic
cultur
demand
freshli
kill
meat
fish
produc
region
eg
guangdong
provinc
china
increas
affluenc
led
prolifer
market
hous
rang
live
wild
anim
speci
civet
cat
pictur
link
restaur
trade
servic
demand
exot
food
viru
adapt
humantohuman
transmiss
later
part
outbreak
asymptomat
infect
seem
rare
peculiar
sarscov
transmiss
also
evid
transmiss
infrequ
first
five
day
ill
unlik
transmiss
influenza
rel
ineffici
household
set
despit
sar
fearsom
reput
global
spread
averag
number
secondari
infecti
case
gener
one
case
r
low
contrast
r
influenza
rang
ref
although
uniqu
sar
superspread
event
affect
individu
disproportion
contribut
transmiss
characterist
outbreak
factor
underli
superspread
phenomenon
sar
poorli
understood
may
includ
coinfect
virus
host
factor
well
behavior
environment
factor
clinic
symptom
sarscov
infect
lower
respiratori
tract
diseas
besid
fever
malais
lymphopenia
affect
individu
slightli
decreas
platelet
count
prolong
coagul
profil
mildli
elev
serum
hepat
enzym
chest
radiographi
reveal
infiltr
subpleur
consolid
ground
glass
chang
compat
viral
pneumon
although
main
clinic
symptom
sever
respiratori
ill
sarscov
actual
caus
infect
organ
affect
individu
wateri
diarrhea
viru
cultur
fece
urin
well
respiratori
tract
addit
rtpcr
identifi
viru
serum
plasma
peripher
blood
leucocyt
individu
sar
also
pronounc
peripher
tcell
lymphocytopenia
number
cell
reduc
onethird
individu
tcell
count
less
cellsmm
ref
suggest
increas
suscept
secondari
infect
mechan
underli
tcell
lymphopenia
remain
elucid
around
individu
sar
requir
manag
intens
care
unit
overal
fatal
rate
world
health
organ
http
wwwwhointcsrsarsenwhoconsensuspdf
age
depend
diseas
sever
mortal
notabl
outbreak
mortal
rate
affect
individu
hong
kong
old
respect
world
health
organ
http
wwwwhoint
csrsarsenwhoconsensuspdf
none
infect
sarscov
hong
kong
diseas
sever
enough
requir
intens
care
mechan
ventil
progress
age
depend
mortal
total
explain
comorbid
factor
underli
biolog
basi
remain
unclear
quantit
studi
viral
load
provid
insight
pathogenesi
sar
viral
load
higher
lower
respiratori
tract
upper
airway
viral
load
upper
respiratori
tract
fece
low
first
day
peak
around
day
ill
mark
contrast
viral
load
influenza
peak
soon
onset
clinic
symptom
unusu
featur
sarscov
infect
explain
low
transmiss
earli
ill
also
explain
poor
diagnost
sensit
firstgener
rtpcr
diagnost
test
upper
respiratori
tract
fecal
specimen
collect
earli
ill
review
ref
affect
individu
high
serum
viral
load
poor
prognosi
day
ill
high
viral
load
nasopharyng
aspir
fece
serum
well
detect
viru
multipl
anatom
site
independ
predict
advers
clinic
outcom
serial
studi
viral
load
throughout
ill
also
reflect
clinic
outcom
taken
togeth
find
suggest
poor
clinic
outcom
associ
continu
uncontrol
viral
replic
sarscov
rna
invari
detect
lung
individu
die
sar
viral
load
higher
die
earlier
cours
ill
day
respiratori
tract
affect
individu
die
first
ten
day
ill
show
diffus
alveolar
damag
mix
alveolar
infiltr
lung
edema
hyalin
membran
format
macrophag
promin
compon
cellular
exud
alveoli
lung
interstitium
multinucl
syncytia
macrophag
epitheli
cell
origin
sometim
seen
later
diseas
immunohistochemistri
situ
hybrid
electron
microscopi
autopsi
tissu
biopsi
unequivoc
demonstr
sarscov
replic
pneumocyt
lung
enterocyt
intestin
individu
report
viru
detect
situ
hybrid
immunohistochemistri
tissu
await
confirm
electron
microscopi
larg
small
intestin
viru
replic
enterocyt
viral
particl
primarili
seen
apic
surfac
enterocyt
rare
glandular
epitheli
cell
villou
atrophi
cellular
infiltr
intestin
epithelium
pathogen
mechan
respons
wateri
diarrhea
individu
sar
unclear
human
intestin
epitheli
cell
line
support
product
replic
sarscov
gene
express
array
shown
viru
replic
associ
express
antiapoptot
host
cellular
respons
perhap
explain
lack
enterocyt
destruct
vivo
studi
use
pseudotyp
lentivirus
carri
spike
membran
envelop
surfac
glycoprotein
sarscov
fig
separ
combin
demonstr
spike
protein
nece
sari
suffici
viru
attach
suscept
cell
sarscov
spike
protein
use
mechan
similar
class
fusion
protein
mediat
membran
fusion
consensu
whether
viru
entri
occur
phdepend
receptormedi
endocytosi
direct
membran
fusion
cell
surfac
receptor
sarscov
identifi
metallopeptidas
ref
solubl
ectodomain
block
sarscov
infect
amino
acid
spike
protein
requir
interact
ref
coronavirus
use
differ
cell
receptor
enter
cell
either
mean
fusion
plasma
membran
receptormedi
endocytosi
immunostain
techniqu
identifi
surfac
type
pneumocyt
enterocyt
part
small
intestin
proxim
tubular
cell
kidney
local
explain
document
tissu
tropism
sarscov
lung
gastrointestin
tract
isol
urin
notabl
colon
enterocyt
lack
protein
express
although
sarscov
replic
occur
colon
epithelium
contrast
wherea
strongli
express
endotheli
cell
small
larg
arteri
vein
tissu
studi
smooth
muscl
cell
intestin
tract
evid
viru
infect
site
lack
viru
infect
tissu
express
put
receptor
prompt
question
whether
coreceptor
requir
success
viru
infect
vascul
known
occur
individu
sar
relat
infect
endotheli
cell
unknown
basal
layer
nonkeratin
squamou
epithelium
upper
respiratori
tract
express
ref
undamag
epithelium
nasopharynx
unlik
support
sarscov
replic
receptor
viru
entri
independ
express
may
exist
pseudotyp
viru
contain
spike
protein
also
shown
bind
dendrit
cellspecif
intercellular
adhes
molecul
nonintegrin
dcsign
dcsign
typeii
transmembran
adhes
molecul
found
dendrit
cell
consist
ctype
lectin
domain
recogn
carbohydr
residu
varieti
pathogen
unlik
receptor
pneumocyt
enterocyt
dcsign
permit
sarscov
infect
dendrit
cell
instead
bind
sarscov
dcsign
allow
dendrit
cell
transfer
infecti
sarscov
suscept
target
cell
similar
mechan
describ
dengu
viru
human
immun
defici
viru
hiv
cytomegaloviru
may
relev
sar
pathogenesi
mani
detail
sarscov
pathogenesi
remain
elucid
develop
fulllength
infecti
cdna
clone
sarscov
permit
precis
manipul
viru
genom
help
understand
viral
determin
pathogenesi
sever
inflammatori
cytokin
chemokin
chemotact
monocyt
neutrophil
elev
adult
children
sar
increas
level
monocytetrop
chemokin
may
contribut
promin
monocyt
macrophag
infiltr
observ
lung
increas
chemokin
occur
viral
diseas
eg
influenza
uniqu
featur
sar
addit
elispot
assay
peripher
blood
leukocyt
reveal
prolong
immunolog
dysregul
individu
sar
difficult
evalu
overal
pathogen
signific
find
immunolog
marker
peripher
blood
alway
reflect
local
microenviron
lung
genet
factor
associ
suscept
sever
sar
investig
hlab
associ
sever
sar
diseas
taiwan
hong
kong
hlab
also
associ
diseas
suscept
resist
sar
coinherit
b
significantli
higher
individu
sar
gener
popul
mechan
underli
diseas
associ
remain
elucid
key
develop
effect
antivir
drug
vaccin
sarscov
develop
anim
model
sar
tabl
sarscov
seem
caus
infect
cynomolg
macaqu
follow
intratrach
inocul
wherea
research
find
evid
diseas
patholog
reminisc
seen
individu
die
sar
show
sarscov
antigen
viral
particl
pneumocyt
infect
macaqu
other
find
evid
mild
upperairway
diseas
low
level
viru
rtpcr
differ
outcom
may
reflect
differ
viral
strain
preexposur
histori
age
anim
rout
inocul
stage
infect
necropsi
perform
factor
anim
model
includ
ferret
cat
golden
syrian
hamster
mice
african
green
monkey
tabl
anim
model
support
viral
replic
upper
lower
respiratori
tract
ferret
hamster
also
develop
notabl
lung
patholog
infect
cat
ferret
transmit
sarscov
noninfect
anim
held
cage
natur
asymptomat
infect
cat
document
commun
outbreak
amoy
garden
hong
kong
world
health
organ
http
wwwwhointcsrsarsen
whoconsensuspdf
anim
model
sar
differ
natur
human
diseas
period
infect
peak
diseas
patholog
peak
viral
load
shorter
found
human
diseas
diseas
patholog
present
selflimit
rare
progress
fatal
outcom
occur
sar
also
accur
reproduc
intestin
compon
human
diseas
model
provid
option
present
avail
address
question
relev
therapeut
vaccin
develop
provid
use
inform
provid
limit
recogn
sever
potenti
antivir
agent
evalu
vitro
test
anim
model
screen
current
avail
antivir
drug
chemic
librari
reveal
interferon
glycyrrhizin
baicalin
reserpin
niclosamid
luteolin
proteas
inhibitor
vitro
activ
sarscov
differ
vitro
suscept
sarscov
interferon
ifn
ribavirin
probabl
relat
differ
test
method
use
overal
leukocyt
hiv
proteas
inhibitor
especi
nelfinavir
consist
activ
vitro
consid
anim
studi
random
placebocontrol
clinic
trial
type
interferon
render
uninfect
cell
refractori
sarscov
replic
mxaindepend
mechan
wherea
hiv
proteas
inhibitor
may
block
activ
main
sarscov
proteinas
far
interferon
test
anim
model
cynomolg
macaqu
pegyl
provid
prophylaxi
margin
effect
earli
treatment
random
placebocontrol
trial
perform
antivir
drug
although
treatment
studi
use
histor
control
suggest
clinic
benefit
combin
proteas
inhibitor
ribavirin
rapid
sarscov
genom
sequenc
determin
structur
potenti
drug
target
predict
function
properti
sarscov
protein
base
prior
knowledg
homolog
coronavirus
allow
identif
potenti
new
drug
target
peptid
deriv
region
spike
protein
shown
block
viru
infect
albeit
much
higher
molar
concentr
similar
inhibitor
need
prevent
hiv
entri
short
interf
rna
also
seem
effect
decreas
viral
replic
cell
line
remain
experiment
strategi
rather
one
immedi
amen
clinic
applic
screen
combinatori
chemic
librari
identifi
inhibitor
sar
proteas
helicas
spikeproteinmedi
cell
entri
success
treatment
influenza
antivir
drug
must
administ
within
hour
diseas
onset
obtain
substanti
clinic
effect
sarscov
load
increas
day
ill
light
correl
high
viral
load
second
week
ill
advers
outcom
window
opportun
antivir
therapi
may
wider
much
scientif
effort
focus
develop
vaccin
protect
futur
outbreak
sarscov
commerci
viabil
develop
vaccin
sarscov
ultim
depend
whether
viru
reemerg
near
futur
discuss
unlik
futur
outbreak
reach
global
proport
nevertheless
vaccin
passiv
immun
would
relev
context
protect
highrisk
individu
laboratori
healthcar
worker
vaccin
could
also
consid
set
farmedgameanim
trade
farm
civet
human
consumpt
continu
short
time
sinc
viru
identifi
substanti
progress
made
toward
develop
vaccin
immunodomin
band
tcell
epitop
sarscov
defin
natur
human
infect
sarscov
lead
longliv
neutral
antibodi
respons
immun
sera
crossneutr
divers
human
sarscov
suggest
activ
immu
press
nizat
sar
may
feasibl
proposit
far
known
instanc
human
reexposur
sarscov
confirm
natur
acquir
immun
respons
confer
protect
reinfect
sarscov
spike
envelop
membran
nucleocapsid
protein
individu
express
attenu
parainfluenza
type
vector
recombin
express
spike
protein
induc
neutral
antibodi
protect
challeng
hamster
tabl
mucos
immun
african
green
monkey
parainfluenzaspik
protein
chimer
viru
led
neutral
antibodi
protect
viral
replic
upper
lower
respiratori
tract
challeng
live
sarscov
spike
proteinencod
dna
vaccin
stimul
neutral
antibodi
product
protect
liveviru
challeng
mice
studi
confirm
assumpt
spike
protein
domin
protect
antigen
sar
experi
use
adopt
transfer
tcell
deplet
show
humor
immun
alon
confer
protect
vaccin
strategi
includ
use
nake
dna
adenovir
vector
modifi
vaccinia
ankara
inactiv
whole
viru
mani
investig
optim
codon
usag
gene
target
improv
express
summari
vaccin
base
spike
protein
seem
induc
neutral
antibodi
respons
carri
nucleoprotein
induc
nucleoproteinspecif
cellmedi
immun
thu
far
four
studi
use
live
sarscov
challeng
immun
anim
tabl
inactiv
vaccin
alum
adjuv
induc
neutral
antibodi
mice
enter
phase
human
clinic
trial
china
experi
coronaviru
vaccin
anim
relev
sar
vaccin
develop
one
problem
face
anim
coronaviru
vaccin
strain
variat
among
field
isol
lead
variabl
vaccin
efficaci
concern
experi
felin
infecti
periton
coronaviru
prior
immun
led
enhanc
diseas
rather
protect
case
sarscov
neither
vaccin
passiv
transfer
antibodi
yet
report
lead
diseas
enhanc
challeng
live
sarscov
occur
soon
immun
whether
wane
immun
low
titer
antibodi
lead
sar
diseas
enhanc
remain
unclear
recent
suggest
immun
ferret
becam
ill
challeng
clearli
need
confirm
refut
passiv
transfer
immun
serum
protect
naiv
mice
sarscov
infect
hyperimmun
globulin
suffici
neutral
activ
use
human
could
prepar
pool
convalesc
human
plasma
hors
immun
inactiv
vaccin
altern
monoclon
antibodi
suffici
neutral
antibodi
activ
develop
screen
phagedisplay
antibodi
librari
immort
bcell
repertoir
convalesc
sar
individu
epsteinbarr
viru
tabl
one
block
receptor
interact
bind
spike
protein
domain
passiv
immun
ferret
mice
effect
suppress
viral
replic
lung
less
nasopharynx
random
placebo
control
trial
evalu
antibodi
therapi
preor
postexposur
prophylaxi
atrisk
group
sar
outbreak
retrospect
analysi
outcom
limit
human
studi
use
human
sar
convalesc
plasma
suggest
passiv
immun
obviou
advers
effect
antigen
divers
sarscovlik
precursor
virus
wildanim
reservoir
undefin
event
new
interspeci
transmiss
event
prompt
anoth
sar
outbreak
crossprotect
afford
current
vaccin
construct
base
human
sarscov
unknown
like
influenc
efficaci
passiv
activ
immun
strategi
sar
provid
pain
remind
global
impact
emerg
infecti
diseas
illustr
microb
evolutionari
drive
preserv
propag
gene
exploit
new
opportun
nich
creat
modern
societi
interspeci
transmiss
virus
human
clearli
occur
throughout
human
histori
recent
develop
allow
sarscov
increas
opportun
adapt
humantohuman
transmiss
subsequ
spread
global
particular
larg
central
wet
market
hospit
prove
venu
amplif
transmiss
human
burgeon
increas
intern
travel
current
million
travel
annual
explod
local
outbreak
emerg
infect
potenti
pandem
recent
emerg
infecti
diseas
threat
zoonot
origin
need
better
understand
microbi
ecolog
livestock
wildlif
context
increas
attent
research
fund
direct
prepared
combat
bioterror
threat
relev
note
natur
remain
greatest
bioterrorist
although
microb
caus
commerci
import
diseas
livestock
well
studi
organ
pose
threat
human
health
necessarili
one
known
caus
diseas
livestock
matter
wildlif
nipah
viru
hendra
viru
sarscov
wildlif
reservoir
furthermor
present
concern
possibl
role
play
wild
bird
duck
mainten
spread
avian
influenza
asia
greater
understand
viral
ecolog
appar
healthi
domest
anim
wildlif
therefor
import
exampl
attent
ecolog
studi
aris
nipah
viru
sar
outbreak
alreadi
led
identif
number
new
virus
includ
tioman
menangl
australian
bat
lyssaviru
novel
group
coronaviru
known
associ
human
livestock
diseas
priorit
research
effort
assess
public
health
relevanceif
anyof
find
pose
challeng
three
incid
laboratoryacquir
sar
arisen
biohazard
level
laboratori
commun
transmiss
aris
one
world
health
organ
http
wwwwprowhoint
incid
associ
laps
biohazard
level
practic
sarscov
safe
handl
biohazard
level
laboratori
provid
biohazard
level
practic
rigor
compli
hospit
healthcar
worker
learn
cost
sarscov
unforgiv
viru
one
laps
may
one
mani
irrelev
whether
laps
occur
biohazard
level
laboratori
despit
impress
speed
scientif
understand
diseas
global
success
contain
sar
owe
much
tradit
public
health
method
clinic
case
identif
contact
investig
infect
control
healthcar
facil
patient
isol
commun
contain
quarantin
applic
measur
modern
societi
control
sar
highlight
sever
ethic
medic
dilemma
mani
aros
need
balanc
individu
freedom
common
good
sar
signal
paradigm
shift
intern
public
health
highlight
need
rapid
inform
exchang
regard
unusu
infecti
diseas
outbreak
possibl
need
coordin
global
respons
emerg
infecti
diseas
threat
earli
stage
outbreak
act
independ
issu
travel
alert
geograph
specif
travel
advisori
without
express
consent
countri
affect
need
measur
acknowledg
post
hoc
member
state
volum
number
decemb
natur
medicin
supplement
world
health
assembl
meet
may
formal
empow
take
action
necessari
futur
although
futur
emerg
pandem
eg
influenza
transmiss
earli
ill
may
quell
similar
measur
success
contain
sar
remain
triumph
global
public
health
